全文获取类型
收费全文 | 778篇 |
免费 | 38篇 |
国内免费 | 28篇 |
专业分类
儿科学 | 71篇 |
妇产科学 | 10篇 |
基础医学 | 72篇 |
口腔科学 | 14篇 |
临床医学 | 52篇 |
内科学 | 100篇 |
皮肤病学 | 15篇 |
神经病学 | 6篇 |
特种医学 | 160篇 |
外科学 | 58篇 |
综合类 | 122篇 |
预防医学 | 25篇 |
药学 | 57篇 |
1篇 | |
肿瘤学 | 81篇 |
出版年
2023年 | 7篇 |
2022年 | 3篇 |
2021年 | 4篇 |
2020年 | 7篇 |
2019年 | 4篇 |
2018年 | 11篇 |
2017年 | 13篇 |
2016年 | 10篇 |
2015年 | 8篇 |
2014年 | 15篇 |
2013年 | 26篇 |
2012年 | 25篇 |
2011年 | 24篇 |
2010年 | 29篇 |
2009年 | 34篇 |
2008年 | 30篇 |
2007年 | 41篇 |
2006年 | 30篇 |
2005年 | 20篇 |
2004年 | 23篇 |
2003年 | 15篇 |
2002年 | 17篇 |
2001年 | 13篇 |
2000年 | 12篇 |
1999年 | 17篇 |
1998年 | 41篇 |
1997年 | 37篇 |
1996年 | 39篇 |
1995年 | 25篇 |
1994年 | 21篇 |
1993年 | 21篇 |
1992年 | 10篇 |
1991年 | 10篇 |
1990年 | 9篇 |
1989年 | 25篇 |
1988年 | 19篇 |
1987年 | 15篇 |
1986年 | 22篇 |
1985年 | 20篇 |
1984年 | 5篇 |
1983年 | 5篇 |
1982年 | 17篇 |
1981年 | 9篇 |
1980年 | 12篇 |
1978年 | 6篇 |
1977年 | 9篇 |
1976年 | 9篇 |
1975年 | 7篇 |
1955年 | 2篇 |
1953年 | 2篇 |
排序方式: 共有844条查询结果,搜索用时 15 毫秒
41.
42.
43.
44.
45.
46.
Paulides M Stöhr W Laws HJ Graf N Lakomek M Berthold F Schmitt K Niggli F Jürgens H Bielack S Koscielniak E Klingebiel T Langer T 《Vaccine》2011,29(8):1565-1568
Background
It is known that antineoplastic treatment may induce secondary immunodeficiency, but studies after childhood sarcoma are rare. Since 1998, the Late Effects Surveillance System (LESS) of the German Society for Paediatric Oncology and Haematology (GPOH) prospectively registers late effects in soft tissue-, osteo- and Ewing's sarcoma patients treated within the therapy trials EICESS-92/EURO-E.W.I.N.G.-99, CWS-96/CWS-2002P, COSS-96 in Austria, Germany and Switzerland.Patients and methods
Antibody levels (AL) against diphtheria and tetanus were used as markers for immunity and classified according to established guidelines for protective AL values. There were 47 eligible relapse-free patients < 21 years of age (31 males; 10 osteosarcoma, 12 Ewing's and 25 soft tissue sarcoma patients). Median age at diagnosis was 9.6 (interquartile range: 4.4-14.7) years.Results
A median 7.2 (3.7-12.2) months after end of antineoplastic therapy, in 28% (13/47; 95% CI 16-43%) of patients there were no protective AL (<0.1 IU/ml) against diphtheria and/or tetanus. Diphtheria and tetanus AL were positively correlated (r = 0.39; p = 0.007). In multivariable analysis, the type of treatment had no effect on AL, similar to tumour type and time of examination after treatment end. Younger patients had significantly lower AL against tetanus (p = 0.009) and girls had significantly lower AL against diphtheria than boys (p = 0.015).Conclusion
Lack of protective AL against tetanus and/or diphtheria is frequent after childhood sarcoma treatment. Prospective surveillance of immunity and, if indicated, re-immunization is warranted in patients treated for childhood cancer. 相似文献47.
MAGNOLOL REDUCES INFARCT SIZE AND SUPPRESSES VENTRICULAR ARRHYTHMIA IN RATS SUBJECTED TO CORONARY LIGATION 总被引:7,自引:0,他引:7
1. Magnolol is an active component of Magnolia officinalis. It is 1000-times more potent than α-tocopherol in inhibiting lipid peroxidation in rat heart mitochondira. In the present study, the in vivo antiarrhythmic and anti-ischaemic effects of magnolol in coronary ligated rats were investigated. 2. Male Sprague-Dawley rats were anaesthetized with urethane. Magnolol, at dosages of 10?7, 10?8 and 10?9 g/kg, was adminstered intravenously 15 min before ligation of the coronary artery. 3. The incidence and duration of ventricular tachycardia and ventricular fibrillation during 30 min coronary ligation were significantly reduced by magnolol. Ventricular arrhythmias during 10 min reperfusion after the relief of coronary ligation were also reduced. 4. In rats subjected to 4h coronary ligation, 10?7 and 10?8 g/kg magnolol significantly reduced infarct size. 5. We conclude that magnolol may protect the myocardium against ischaemic injury and suppress ventricular arrhythmia during ischaemia and reperfusion. 相似文献
48.
目的观察小分割分次立体定向放射治疗(fractionated stereotatic radiation therapy,FSRT)脑转移瘤的近期疗效.方法15例病人单纯全脑外照射(WBRT组),中间平面剂量20~40Gy/10~20次/2~4周.17例病人接受FSRT(FSRT组),每次分次剂量为2.5~3.0Gy.其中11病人行单纯FSRT,中心总剂量为30~60Gy/1 0~20次/2~4周;6例病人先行WBRT,然后行FSRT,中心总剂量为46~60Gy/5~6周.结果KSP评分增加10分以上者,WBRT组为5 3.3%,FSRT组为82.4%.(P<0.05).WBRT组有效率(CR PR)为50.0%;FSRT组有效率(CR PR)为80.0%.中位生存率:WBRT组为3.5月,FSRT组为10.0月.结论FSRT能有效地控制脑转移瘤,减轻神经系统症状,提高生存质量,延长病人生存期,而没有增加副作用,值得临床推广应用. 相似文献
49.